Deep brain stimulation (DBS) in the subgenual cingulated gyrus (SCG) is a promising new technique that may provide sustained remission in resistant major depressive disorder (MDD). Initial studies reported a significant early improvement in patients, followed by a decline within the first month of treatment, an unexpected phenomenon attributed to potential placebo effects or a physiological response to probe insertion that remains poorly understood. Here we characterized the behavioural antidepressantlike effect of DBS in the rat medial prefrontal cortex, focusing on modifications to rodent SCG correlate (prelimbic and infralimbic (IL) cortex). In addition, we evaluated the early outcome of DBS in the SCG of eight patients with resistant MDD involved in a clinical trial. We found similar antidepressant-like effects in rats implanted with electrodes, irrespective of whether they received electrical brain stimulation or not. This effect was due to regional inflammation, as it was temporally correlated with an increase of glialfibrillary-acidic-protein immunoreactivity, and it was blocked by anti-inflammatory drugs. Indeed, inflammatory mediators and neuronal p11 expression also changed. Furthermore, a retrospective study indicated that the early response of MDD patients subjected to DBS was poorer when they received anti-inflammatory drugs. Our study demonstrates that electrode implantation up to the IL cortex is sufficient to produce an antidepressant-like effect of a similar magnitude to that observed in rats receiving brain stimulation. Moreover, both preclinical and clinical findings suggest that the use of anti-inflammatory drugs after electrode implantation may attenuate the early anti-depressive response in patients who are subjected to DBS.
INTRODUCTION
Deep brain stimulation (DBS) in the subgenual cingulated gyrus (SCG) is a promising non-pharmacological therapeutic alternative to treat resistant major depressive disorder (MDD). [1] [2] [3] Interestingly, these studies also described an initial and unexpected short-term antidepressant effect. This effect was described as a biphasic effect with a large initial improvement in the first week, followed by a decline and a subsequent progressive improvement that reached a plateau after 6 months. 2 This transient early amelioration of symptoms has also been described in other diseases where DBS has been employed, [4] [5] [6] [7] and it has been attributed to a possible placebo effect. However, an alternative physiological cause has also been proposed, referred to as an 'insertional effect', involving local responses to the introduction of the probe into the neural tissue. 8 It is plausible that such neurophysiological changes could account for the early antidepressant effects of DBS and that these transient benefits could reduce the time required to reach remission.
To address this question, we characterized the antidepressantlike effect of the DBS procedure in the medial prefrontal cortex (PFC) of rats, which covers the prelimbic (PL) and infralimbic (IL) cortex, and that represents the rodent region homologous to the human SCG (Brodmann areas (BA) 24/25). 9, 10 In addition, we evaluated the early phase of DBS therapy in a controlled clinical trial of patients diagnosed with treatment-resistant MDD. Our data suggest that early DBS response is induced by local inflammation, which is supported by the fact that anti-inflammatory drugs used peri-operatively counteract this beneficial effect. 
MATERIALS AND METHODS Animals
Male
Surgery and stimulation procedure
Once anaesthetized (100 mg kg À 1 ketamine, 12 mg kg À 1 xylazine, intraperitoneal), the rats were placed in a stereotaxic apparatus for surgery. The stimulation target chosen was the IL cortex (AP þ 3 from bregma, L ± 0.5 from the midline suture, DV 4.8 mm from the dura mater). In another set of experiments, the electrodes were implanted in the PL cortex (AP þ 3.2, L±0.5, DV 3 mm) and the cingulate cortex (AP þ 2.7, L±0.5, DV 1.3 mm) (Supplementary Figure S2) . 11 The bipolar stimulating electrodes were two stainless-steel enamel-coated wires (California Fine Wire, Grover Beach, CA, USA) with 1 mm of exposed surface. The stimulation protocol consisted of monophasic square wave pulses (100 mA, 130 Hz and 90 ms). 12 
Forced swimming test (FST)
FST was performed in large plastic cylinders filled with water for a period of 15 min in the first swimming session (pre-test) and again 24 h later for 5 min under the same conditions (test). 13 Behaviour (immobility, swimming or climbing) was assessed at 5-s intervals throughout the duration of the test session using customized software (Red-Mice, Cadiz, Spain). After FST, rats were killed and studied by western blotting, enzyme-linked immunosorbent assay or immunohistochemistry.
Open field test
Locomotor activity was measured using an open field apparatus (45 Â 45 Â 35 cm 3 ). Total distance travelled was measured over testing period using S.M.A.R.T (Spontaneous Motor Activity Recording and Tracking: Panlab, S.L., Barcelona, Spain).
Chronic unpredictable stress (CUS)
One group of animals was subjected to CUS for a period of 5 consecutive weeks (Figure 4a ). Four weeks after the beginning of the CUS, the animals were split into two groups: naive or DBS-off-IL (electrodes implanted and kept in place but no stimulation was delivered). During the entire experiment, No_CUS animals were housed in a separate room. Preference for sucrose solutions over water was monitored on a weekly basis. Furthermore, the animals were also assessed in the FST.
Western blotting
Rats were killed by decapitation, and the PL and IL cortex were removed bilaterally. Equal amounts of protein from tissue homogenates were separated in SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) gels and transferred to polyvinylidene difluoride membranes. All samples were incubated with the primary antibody (mouse anti-p11, 1:500; Abcam, Cambridge, UK; rabbit anti-cyclooxygenase-1 (COX1), -2 (COX2), -tumour necrosis factor receptor type 1 (TNFR1) and 2 (TNFR2), 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Membranes were washed and incubated with corresponding horseradish peroxidase-conjugated secondary antibody (1:10000 for p11 and 1:3000 for the rest of proteins). Antibody binding was detected by enhanced chemiluminescence, and appropriate film expositions were acquired with Versadoc 5000 (Bio-Rad Laboratories, Madrid, Spain) and were quantified with Image J Software (NIH, Bethesda, MD, USA). The protein levels were normalized using a-tubulin or b-actin.
Enzyme-linked immunosorbent assay
Levels of TNFa, interleukin-1b (IL-1b), interleukin-6 (IL-6) and interferon-g were measured in the tissue homogenates from the PL and IL cortex using commercially available kits (R&D Systems, Minneapolis, MN, USA) following the manufacturer's instructions.
Immunohistochemistry
Coronal brain sections (30 mm) were first incubated with a rabbit antibody against glial-fibrillary-acidic-protein (anti-GFAP, 1:2000; DAKO, Glostrup, Denmark) and later with a biotinylated secondary antibody (Jackson Immuno Research Laboratories, West Grove, PA, USA). Immunodetection was achieved using an ABC kit and by reaction with 3,3-diaminobenzidine tetrahydrochloride.
To evaluate p11 expression, sections were incubated with the two primary antibodies: chicken anti-p11 (1:200; Abcam) and mouse against Image analysis GFAP expression was evaluated by densitometry with an Olympus-BX60 (Olympus, Hamburg, Germany) microscope under homogeneously lit bright-field illumination, digitalized using an Olympus-DP71 digital camera and Cell F software (Olympus). Photomicrographs were taken at Â 20 magnification and converted into 8-bit images using Image J software (NIH). Grey levels were then converted to optical densities and the mean grey values of IL cortex per section was calculated using the following formula: (ROI mean grey-GBLR mean grey)/(ULR mean grey-GBLR mean grey); where 'ROI' ¼ region of interest, 'GBLR' ¼ glass background labelling region and 'ULR' ¼ unspecific labelling region). In each group, values of GFAP expression were expressed as the mean grey value of densitometry/ section. The co-localization of p11 and MAP2 or GFAP immunolabeling was evaluated using a Leica Spectra Confocal microscope (Leica Microsystems GmbH, Wetzlar, Germany). Each multi-fluorophore image was separated into individual images and converted into 8-bit images.
Drugs
Imipramine, para-Chlorophenyl-alanine methyl ester (pCPA) and indomethacin were obtained from Sigma-Aldrich (St Louis, MO, USA) and ibuprofen from Zambó n S.A. (Barcelona, Spain).
Human studies
Subjects were recruited in Santa Creu i Sant Pau Hospital (Barcelona, Spain), and they were fully informed of the aims and risks of the study. The patient group comprised of eight patients (six female/two male) with refractory MDD according to DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision) criteria (clinical and demographic characteristics and inclusion/exclusion criteria are described in 14 ) . Depressive symptoms were rated according to the17-item Hamilton Depression Rating Scale (HDRS-17). Patients were defined as responders if they exhibited a decrease of at least 50% in their HDRS-17 score. Remission was considered to be achieved in patients with a score of p8 in the HDRS-17 scale.
DBS electrodes were implanted in the white matter adjacent to the SCG region (BA 24/25) using a Leksell-G stereotactic frame (Elekta Instruments, Stockholm, Sweden). Quadripolar electrodes (Model-3387; Medtronic, Minneapolis, MN, USA) were implanted bilaterally, guided by an intraoperative stereotactic magnetic resonance image and stereotactic cerebral computer tomography. The leads were connected to a programmable internal capsule pulse generator (Medtronic). Chronic stimulation began within 48 h after surgery in all the patients. Stimulating parameters (3.5-5 V, 135 Hz, 120-210 ms) were adjusted during subsequent visits if the patient failed to show improvement.
Statistics
The data were expressed as the mean ± s.e.m. in animal studies and mean±s.d. in clinical studies. The statistical significance was assessed using an unpaired Student's t-test, one-or two-way or repeated-measures analysis of variance followed by a Bonferroni's test (Supplementary Table S1 ). Significance was defined as Po0.05.
RESULTS

Effect of DBS in the FST
The antidepressant-like effect of DBS was first evaluated 1 week after surgery (Figures 1a-c and Supplementary Figure S1A) . FST analysis revealed a significant decrease in immobility in DBS-on-IL when compared with naive and sham (F (3,36) ¼ 14.15, Po0.001 and Po0.01, respectively), accompanied by an increase in swimming (F (3,36) ¼ 14.54, Po0.001 in each case). Strikingly, similar results were found in the DBS-off-IL group in the absence of stimulation. Indeed, animals implanted with electrodes exhibited significant differences in immobility and swimming (Po0.001 versus naive and Po0.05 versus sham). Furthermore, no differences were detected in locomotor activity between groups, precluding a motor component in the observed effects in the FST (Supplementary Figure S3) .
Whether the results observed were specific to a given brain area was determined by implanting the electrode into the PL and cingulate cortex, which produced no antidepressant-like effect in either case (PL: immobility t ¼ 0.10, df ¼ 12; swimming t ¼ 0. 35 (Figures 1a-c) . Overall, these findings demonstrate that electrode placement as deep as the IL cortex exerts an antidepressant-like effect in the FST.
Next, as electrode implantation (DBS-off-IL) induced an increase in swimming, animals were pre-treated with pCPA to determine whether this antidepressant-like activity was mediated by effects on 5-hydroxytryptamine (5-HT) transmission. Pre-treatment with pCPA increased immobility and diminished the active behaviours in the DBS-off-IL (Figure 1d and Supplementary Figure S1B) . Furthermore, as elevating the amount of p11 in the PFC seems to be essential for selective serotonin reuptake inhibitors to exert their antidepressant action, 15, 16 we evaluated p11 expression in the PL and IL cortex (Figures 1e-h ). The amount of p11 increased significantly in DBS-off-IL as compared with naive (F (3, 20) ¼ 9.10, Po0.01) and, as expected, after imipramine treatment (Po0.05). Furthermore, co-immunolabeling showed that p11 specifically co-localized with MAP2 (neuronal marker) and that p11 expression was visibly higher in DBS-off-IL animals at a distance of 500-700 mm from the site of injury (Supplementary Figures S4  and S5 ). No co-localization was seen with GFAP (astrocyte marker).
Temporal effect of electrode implantation Independent groups of animals were evaluated in the FST 1, 2 or 6 weeks after surgery (Figures 2a-c and Supplementary Figure S1C) . Results showed that the antidepressant-like effect in DBS-off-IL was conserved for 2 weeks after surgery, as witnessed by a decrease in immobility and an increase in swimming when compared with naive (Po0.001 in each case). However, these effects were absent 6 weeks after the implantation of electrodes. Therefore, it is plausible that the inflammatory response produced by surgery is implicated in the antidepressant-like response. 8 Immunohistochemical analysis revealed an increase in GFAP expression in the IL cortex in DBS-off-IL 1 and 2 weeks after surgery when compared with naive (Po0.001 and Po0.01, respectively) and sham-operated rats (Po0.001 and Po0.05, respectively). Furthermore, such an increase was not found after 6 weeks of implantation (Figures 2d-m) .
Additionally, we also explored the effect of electrode insertion soon after surgery (Supplementary Figure S6) . Forty-eight hours after surgery, DBS stimulation was able to produce an antidepressant-like effect compared with naive (DBS-on-IL; Po0.05). However, electrode insertion (DBS-off-IL) does not have such an effect.
Non-steroidal anti-inflammatory drugs (NSAIDs) influence the antidepressant-like effect of probe implantation To determine whether preventing the inflammatory response could counteract the antidepressant-like effect seen 1 week after electrode implantation, animals were pre-treated with indomethacin or ibuprofen (Figure 3a, Supplementary Figures S1D, S7A and Figures S7C-G) . As expected, higher levels of inflammatory mediators (cytokines: IL-1b: Po0.001 and TNFa: Po0.01) and COX1 and COX2 enzymes (Po0.001 both) were found in the DBS-off-IL group (Figures 3g-h) . However, the pretreatment with indomethacin significantly attenuated the amounts of TNFa (Po0.05), as well as COX expression (COX1: Po0.01 and COX2: Po0.001). No changes were found in the levels of other inflammatory cytokines (IL-6 and interferon-g) or in the expression of TNFR1 and TNFR2. Furthermore, p11 expression was also diminished by indomethacin pre-treatment (Po0.001; Figure 3h ).
Effect of electrode implantation in the CUS
The antidepressant-like effect of DBS-off-IL was evaluated in animals submitted to CUS (Figure 4a ), an animal model of depression. A decline in the preference for sucrose solutions over water is considered an index of anhedonic-like behavior, which was already noticeable between stressed and non-stressed rats 1 week after CUS. This difference became particularly pronounced after 4 weeks of stress, at which point the electrodes were implanted. In line with previous data, 17 electrode implantation in the stressed group led to an increase in sucrose preference in the first week (80% DBS-off-IL CUS versus 59% naive CUS; Po0.05) (Figure 4b ). In the FST, naive CUS significantly displayed greater immobility (Po0.05) and less swimming (Po0.05) than the control (naive No_CUS), whereas, as expected, electrode implantation decreased immobility (Po0.05) and increased swimming activity (Po0.01). Interestingly, the implantation of electrodes in the stressed group (DBS-off-IL CUS) caused a decrease in immobility (Po0.001) and an increase in both active movements relative to the naive animals ( Figure 4c ).
The effect of NSAIDs in the early effect of DBS in MDD patients
One week after implantation, all patients showed clear improvements in their symptoms.
14 However, a general reversion was observed soon after (Figure 5a ), as previously reported. 2, 3 Successful implantation in SCG was confirmed, 14 and no significant differences in the HDRS-17 response were detected between the patients who received electrical stimulation in BA24 or BA25 1 month after surgery (t ¼ 2.5, df ¼ 5, P40.05).
Based on our findings in rats, we retrospectively evaluated the post-operative regime of analgesic/anti-inflammatory drug administration in relation to the HDRS-17 score. Patients were split into two groups: the first group included patients who received antiinflammatory drugs (for pain control) during the first month after surgery, while those in the second group received no treatment (Figures 5b and c) . Although all patients received bilateral DBS, similar effects were only observed 1 week post implantation, after which divergent effects were detected between the two groups of ) and periods of no stress. All stressful situations lasted for 10-14 h, and they were applied individually and continuously, day and night. The asterisk indicates sucrose preference (SP) test. The day of surgery (after 4 weeks of CUS) the animals were split between naive (no surgical or pharmacological manipulation) or DBS-off-IL groups (electrodes implanted in the infralimbic (IL) cortex and kept in place but no stimulation was delivered). The forced swimming test (FST) was conducted 1 week after the surgery. (b) The effect of the CUS and the surgery in the SP test. Rats were initially trained to drink a sucrose solution during the habituation period with a two-bottle choice procedure (one containing 1% sucrose solution and the other containing water) for 1 h. The consumption of water or sucrose was measured by weighing the bottles. The position of the two bottles was varied randomly from trial to trial. SP was calculated as SP (%) ¼ (sucrose intake (g)/(sucrose intake (g) þ water intake (g)) Â 100. The animals were deprived of water and food 23 h before the test. During the CUS period, the rats were evaluated once a week with the same procedure. (c) The FST was conducted at the end of the experiment. Graphs represent mean þ s.e.m. Two-way analysis of variance followed by Bonferroni's test: *Po0.05, **Po0.01, ***Po0.001 versus respective naive group; weeks. Almost all the patients who received analgesic/antiinflammatory drugs reached the response criterion after 1 week (3/4), with two of the four patients achieving remission. However, the response deteriorated 2 weeks after surgery, with just one of the four patients meeting the response criteria. Accordingly, the antidepressant efficacy fell substantially over the month, with none of the patients responding by 4 weeks.
DISCUSSION
This translational study demonstrates that the procedure of implanting an electrode into the IL cortex is sufficient to produce benefits in animal models of antidepressant activity. These findings are consistent with the initial effects observed in a series of patients treated for 1 month with DBS. Overall suggest that this early antidepressant effect of DBS is the result of an inflammatory 'insertional effect' provoked by electrode implantation, as it can be blocked by pre-treatment with NSAIDs.
We show here that the mere implantation of electrodes produces an antidepressant-like effect in the FST. This effect was of a similar magnitude to that observed after high frequency stimulation or treatment with imipramine, and analogous effects were found in the CUS model of depression. The electrode's trajectory involves the entire medial PFC, including the IL, PL and cingulate cortex. However, our results show that the electrodes need to be inserted up to the IL to produce an antidepressant-like effect. Indeed, pharmacological inactivation of the IL cortex induces an antidepressant-like effect in the same model used here, 18, 19 and interestingly, the IL cortex and/or the most ventral part of the PL cortex are thought to be the target for the effect of DBS in animal models of depression. 12, 17, 20, 21 Hence, further studies to map the 'insertional effect' and its area of influence would appear to be necessary. Importantly, our findings in animals are consistent with those of a clinical trial in which all patients exhibited a dramatic improvement 1 week after electrode implantation in BA24/25.
14
The integrity of the 5-HT system seems to be essential for the antidepressant nature of this 'insertional effect'. Analysis of active movements in the FST suggested that serotonergic neurotransmission was involved in the antidepressant-like effect, as corroborated by the decrease in active behaviour in DBS-off-IL animals following pCPA administration. Indeed, there is increasing evidence that antidepressant therapies (tricyclic antidepressants, selective serotonin reuptake inhibitors and electroconvulsive therapy) enhance p11 expression, which upregulates the number of 5-HT 1B and/or 5-HT 4 receptors at the cell membrane. 15, 22 This increase in receptor expression influences the efficacy of serotonergic neurotransmission, leading to antidepressant effects. 23 Indeed, when we assessed p11, we found that electrode implantation also increased p11 levels in DBS-off-IL animals, typically in neurons. Moreover, 5-HT 1B and 5-HT 4 receptors are localized in several brain regions linked with depression, and particularly, 5-HT 1B in the cortex. 24 Thus, it seems plausible that electrode insertion would promote p11 expression, which would, in turn, recruit 5-HT 1B receptors and produce antidepressant-like effects. Indeed, it would be of interest to examine 5-HT 1B and/or 5-HT 4 receptor co-expression with p11 in the PFC and other brain regions in DBS-off-IL animals. Interestingly, electrode insertion into depressed animals (DBS-off-IL CUS) increased both swimming and climbing in the FST, suggesting that catecholaminergic neurotransmission, as well as the serotonergic system, may be involved in the antidepressant-like response of depressed animals. Furthermore, the reduced immobility and increased climbing of DBS-on-IL forty-eight hours post surgery suggest that distinct mechanisms are involved in the 'insertional effect' and in the effects of the electrical stimulation.
An important question that deserves attention involves the mechanisms by which the 'insertional effect' produces its benefits. In general, the CNS responds to injury by activating several shortterm repair mechanisms, and thus, it is plausible that these mechanisms might be involved in the antidepressant-like effects observed. In agreement with our hypothesis (Supplementary Figure S8) , intracranial electrode implantation represents an obvious insult that is reflected by transient and local glial activation (reactive astrogliosis: GFAP), which provokes an antidepressant-like effect 1 week later. Accordingly, gliosis was self-limited and coincided temporally with the gradual loss of the antidepressant effect (6 weeks). There is growing evidence that GFAP expression in the PFC is reduced by depression [25] [26] [27] [28] [29] [30] and that GFAP activation occurs in response to electroconvulsive 31, 32 and pharmacological treatment. 25, 33, 34 Thus, the temporal transformation of glia into activated (or reactive) states may lead to the expression of inflammatory mediators that would induce p11, increasing serotonergic neurotransmission and leading to the antidepressant effects observed. Not only does p11 traffic 5-HT receptors to the cell membrane but it also participates in the Oral doses were as follows: acetaminophen, 500 mg/3 times a day; non-steroidal anti-inflammatory drugs: ibuprofen, 600 mg/3 times per day, and metamizole, 575 mg/3 times a day, PS: days post surgery. Graphs represent mean ± s.d. Two-way repeated-measures analysis of variance followed by Bonferroni's test: ***Po0.001 versus untreated patients (n ¼ 4 patients per group).
Early response of deep brain stimulation L Perez-Caballero et al transient reaction to nervous system lesion, 35, 36 and data from cell lines confirm that p11 is regulated by inflammatory molecules like Toll-like receptor-4, nitric oxide and phospolipase A2. [37] [38] [39] Furthermore, p11 expression was also enhanced in DBS-off-IL animals, and it was more strongly expressed close to the insertion site, consistent with an injury-related effect. Once tissue is repaired (homeostasis), p11 levels would decrease and the antidepressant effect will be lost. Moreover, indomethacin counteracts TNFa production and COX expression, and it also blocks the increase in p11 and the antidepressant-like effect, linking local inflammation with the behavioral response. TNFa might be an important participant in this process, because its administration produces an antidepressant-like effect through a p11-dependent mechanism at PFC. 16 This could reflect a direct effect of TNFa, or it may alternatively occur due to the indirect production of neurotrophic factors. [40] [41] [42] Neurotrophic factors, such as brain-derived neurotrophic factor and nerve growth factor, seems to be relevant for antidepressant-like effects in animal models, 43 and they also induce p11 expression. [44] [45] [46] Therefore, p11 production might be induced directly or indirectly by a specific mediator produced by tissue injury, leading to an antidepressant effect. Consequently, p11 blockade by NSAIDs would limit this effect, consistent with data from animal and human studies. Furthermore, our findings do not contradict the idea that brain inflammation might provoke depression. 47, 48 Depression has been suggested as a process of chronic and general inflammation, chronic and unsuccessful immune dysregulation that persists over time. By contrast, electrode insertion causes acute and local inflammation, that is, an active process associated with successful host defense which is limited in time. 49, 50 Thus, local injury in a discrete brain area would promote the activation of mechanisms leading to short-term antidepressant effects.
It is important to note the temporal differences in the effects observed in the animal and clinical studies. We propose that preventive treatment with NSAIDs in rats counteracts the processes triggered by electrode implantation. By contrast, patients received analgesic/anti-inflammatory treatment ad libitum and post surgery, and while the initial inflammatory process appears to have occurred in all patients, it was later compromised by the analgesic/anti-inflammatory treatment administered. Importantly, the DBS trial in humans was an openlabel design in which all patients received stimulation. Future double-blind trials with groups of stimulated and unstimulated patients will provide a better indication of the effects of DBS and further clarify the role of electrode implantation in the associated antidepressant effects. In addition, the existence of a disease other than MDD (a painful condition) that requires NSAIDs treatment may exacerbate depression and/or hinder early efficacy, and this should also be controlled. Overall, the balance between the benefits and risks of using NSAIDs in MDD patients undergoing DBS should be considered. Furthermore, given the magnitude of this type of surgery, other post-operative analgesic options should be explored.
In summary, our rat studies demonstrate that electrode implantation into the IL cortex is sufficient to produce an early antidepressant-like effect, probably through temporary regional inflammation. We suggest that, in addition to the beneficial effect of DBS, there is another effect that also contributes to the early antidepressant response. Based on our clinical findings, we propose that anti-inflammatory drugs routinely used in a preventive and palliative capacity in DBS surgery may counteract the initial antidepressant effects of this approach.
